Features of Dissociation Differentially Predict Antidepressant Response to Ketamine in Treatment-Resistant Depression
Mark J. Niciu, Bridget J. Shovestul, Brittany A. Jaso, Cristan A Farmer, D. Luckenbaugh, Nancy E. Brutsché, Lawrence T. Park, Elizabeth D. Ballard, Carlos A. Zarate
Journal of Affective Disorders February 17, 2018 DOI: 10.1016/j.jad.2018.02.049 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Follow-up study with confirmatory factor analysis and general linear model Peer reviewed |
|---|---|
| Sample size | 126 |
| Population | Treatment-resistant patients with major depressive disorder or bipolar disorder |
| Intervention | Ketamine |
| Dose | 0.5 mg/kg |
| Measures | Clinician-Administered Dissociative States Scale (CADSS), 17-item Hamilton Depression Rating Scale (HAM-D) |
| Topics | Depression Esketamine Ketamine |
| Citations | 134 |
| Key points | Depersonalization was positively related to antidepressant response across all studies and timepoints, while derealization showed a significant effect at only one timepoint in one study, and amnesia was unrelated. |
Abstract
Background: Ketamine induces rapid and robust antidepressant effects, and many patients also describe dissociation, which is associated with antidepressant response. This follow-up study investigated whether antidepressant efficacy is uniquely related to dissociative symptom clusters.
Methods: Treatment-resistant patients with major depressive disorder (MDD) or bipolar disorder (BD) (n=126) drawn from three studies received a single subanesthetic (0.5mg/kg) ketamine infusion. Dissociative effects were measured using the Clinician-Administered Dissociative States Scale (CADSS). Antidepressant response was measured using the 17-item Hamilton Depression Rating Scale (HAM-D). A confirmatory factor analysis established the validity of CADSS subscales (derealization, depersonalization, amnesia), and a general linear model with repeated measures was fitted to test whether subscale scores were associated with antidepressant response.
Results: Factor validity was supported, with a root mean square error of approximation of .06, a comparative fit index of .97, and a Tucker-Lewis index of .96. Across all studies and timepoints, the depersonalization subscale was positively related to HAM-D percent change. A significant effect of derealization on HAM-D percent change was observed at one timepoint (Day7) in one study. The amnesia subscale was unrelated to HAM-D percent change.
Limitations: Possible inadequate blinding; combined MDD/BD datasets might have underrepresented ketamine’s antidepressant efficacy; the possibility of Type I errors in secondary analyses.
Conclusions: From a psychometric perspective, researchers may elect to administer only the CADSS depersonalization subscale, given that it was most closely related to antidepressant response. From a neurobiological perspective, mechanistic similarities may exist between ketamine-induced depersonalization and antidepressant response, although off-target effects cannot be excluded.
Citations in the library
Cited by 85
- Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation American Journal of Psychiatry March 17, 2021
- Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. American Journal of Psychiatry March 29, 2019
- Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine Journal of Neuroscience November 30, 2020
- Long-term safety of ketamine and esketamine in treatment of depression Expert Opinion on Drug Safety April 13, 2022
- A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression Translational Psychiatry June 26, 2020
and 80 more in the library
Cites 15
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Archives of General Psychiatry August 1, 2006
- Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex Journal of Neuroscience April 15, 1997
- NMDAR inhibition-independent antidepressant actions of ketamine metabolites Nature April 24, 2016
- Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial American Journal of Psychiatry August 28, 2013
- A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression Archives of General Psychiatry August 1, 2010
and 10 more in the library